Marksans Pharma Limited

NSEI:MARKSANS 株式レポート

時価総額：₹136.0b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Marksans Pharma マネジメント

マネジメント 基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Mark Saldanha

最高経営責任者

₹68.9m

報酬総額

CEO給与比率69.7%
CEO在任期間9yrs
CEOの所有権43.8%
経営陣の平均在職期間12.9yrs
取締役会の平均在任期間6.2yrs

経営陣の近況

Recent updates

Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Sep 21
Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Jul 28
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

May 31
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Feb 16
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

Jan 26
Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Dec 02
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Jun 21
Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Nov 17
Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Sep 16
This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Sep 01
Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Jun 14
Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

May 27
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Feb 19
Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 04
Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Jan 20
Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Jan 05
Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%

Dec 21
Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%

What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?

Dec 06
What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?

These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely

Nov 19
These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely

CEO報酬分析

Marksans Pharma の収益と比較して、Mark Saldanha の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2024n/an/a

₹3b

Mar 31 2024₹69m₹48m

₹3b

Dec 31 2023n/an/a

₹3b

Sep 30 2023n/an/a

₹3b

Jun 30 2023n/an/a

₹3b

Mar 31 2023₹52m₹48m

₹3b

Dec 31 2022n/an/a

₹2b

Sep 30 2022n/an/a

₹2b

Jun 30 2022n/an/a

₹2b

Mar 31 2022₹38m₹35m

₹2b

Dec 31 2021n/an/a

₹2b

Sep 30 2021n/an/a

₹2b

Jun 30 2021n/an/a

₹3b

Mar 31 2021₹10m₹10m

₹2b

Dec 31 2020n/an/a

₹2b

Sep 30 2020n/an/a

₹2b

Jun 30 2020n/an/a

₹1b

Mar 31 2020₹10m₹10m

₹1b

Dec 31 2019n/an/a

₹879m

Sep 30 2019n/an/a

₹834m

Jun 30 2019n/an/a

₹780m

Mar 31 2019₹10m₹10m

₹804m

Dec 31 2018n/an/a

₹666m

Sep 30 2018n/an/a

₹582m

Jun 30 2018n/an/a

₹463m

Mar 31 2018₹12m₹10m

₹358m

報酬と市場: Markの 総報酬 ($USD 820.16K ) は、 Indian市場 ($USD 474.17K ) の同規模の企業の平均を上回っています。

報酬と収益: Markの報酬は過去 1 年間で 20% 以上増加しました。

CEO（最高経営責任者

Mark Saldanha (52 yo)

9yrs

在職期間

₹68,857,053

報酬

Mr. Mark B. Saldanha, M.Sc. (Maths) & (Stat.)., Dip. (Fin. Mgt.) serves as Promoter and Managing Director of Marksans Pharma Limited, which he joined in October 6, 2005 (alternate name, Glenmark Laboratori...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Mark Saldanha
Non-Independent Executive Chairman & MDno data₹68.86m43.8%
₹ 59.6b
Jitendra Sharma
Chief Financial Officer22.1yrs₹12.84mデータなし
Harshavardhan Panigrahi
Company Secretary15.7yrs₹2.84mデータなし
Sandra Saldanha
Whole-Time Executive Non Independent Director10.1yrs₹7.07m0.073%
₹ 99.2m
Varddhman Jain
Whole-Time Executive Non Independent Director5.8yrs₹18.75mデータなし
Sunil Rane
Senior Vice President of QCno data₹10.61mデータなし
Vishal Bhargava
Director Operationsno dataデータなしデータなし
David Mohammed
Managing Director of Australia Operationsno dataデータなしデータなし
Sathish Kumar
Managing Director of UK Operationsno dataデータなしデータなし
Anjani Kumar
Chief Operating Officer of US Operationsno data₹10.29mデータなし

12.9yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: MARKSANSの経営陣は経験豊富で経験豊富です（平均在職期間は12.8年）。

取締役

名称ポジション在職期間報酬所有権
Mark Saldanha
Non-Independent Executive Chairman & MD9yrs₹68.86m43.8%
₹ 59.6b
Sandra Saldanha
Whole-Time Executive Non Independent Director10.1yrs₹7.07m0.073%
₹ 99.2m
Varddhman Jain
Whole-Time Executive Non Independent Director5.8yrs₹18.75mデータなし
Sunny Sharma
Non-Executive & Non-Independent Director3.2yrsデータなしデータなし
Abhinna Mohanty
Non-Executive & Independent Director5.3yrs₹15.00kデータなし
Shailaja Vardhan
Non-Executive & Independent Director1.4yrs₹300.00kデータなし
Seetharama Buddharaju
Non-Executive & Independent Director13yrs₹25.00kデータなし
Digant Parikh
Non-Executive Independent Director6.6yrs₹400.00kデータなし

6.2yrs

平均在職期間

53.5yo

平均年齢

経験豊富なボード: MARKSANSの 取締役会 は 経験豊富 であると考えられます ( 5.8年の平均在任期間)。